Amy Adams stepped into the role of director of the National Institute of Neurological Disorders and Stroke (NINDS) at the beginning of the year after more than two decades within the National Institutes of Health (NIH) and serving as the institute's acting deputy director. As a lifelong researcher, Dr Adams offers her perspective on how the scientific environment in neurology has been transformed over a decade of work through programs like the NIH BRAIN Initiative. With significant advances in understanding how the brain works and the external factors that impact neurological health, Adams looks ahead to a future in which advances in biomarker validation, genetic therapies, and data utilisation are reshaping how neurological conditions are researched, treated, and understood.
You were appointed Director at the beginning of the year, after more than two decades at NIH and 13 years at NINDS. Can you start by introducing yourself, the NINDS, and your priorities coming into this new responsibility?
I came to NIH after graduate school and postdoctoral research in neurotransmitter signalling and its regulation of behaviour. I was drawn to the NIH by its mission to serve the public and to use scientific knowledge to make the world a better place. I came to NINDS and have never looked back because there is no more compelling question than how the brain and the nervous system work, and how we can use that knowledge to improve neurological health for everyone.
A personal note, my grandmother descended into dementia when I was in high school. That experience drove a lifelong desire to understand how that process unfolds and how we might intervene to preserve the memories and the relationships that define us. It has been a privilege to work toward that goal at NINDS for over a decade.
For those unfamiliar with how NINDS functions, there are two main components. We have an intramural research program with approximately forty faculty members conducting ground-breaking basic, translational, and clinical research on neurological disorders and on the fundamental workings of the brain. At the same time over 80 percent of our funding goes outward, in grants and contracts to researchers, students, and companies at medical schools, universities, and small businesses across every state and, in some cases, internationally. It is through those grants and contracts and cooperative agreements that the majority of our advances in understanding the brain and the nervous system are made.
I step into this directorship at a moment where there is real uncertainty in the research community right now. While our budget has remained stable at just over USD 2.8 billion for the past four years, inflation has not been stable, and the purchasing power of our grants is not what it used to be. Some policy changes have also meant that we are able to make fewer grants than before. So my primary priority is to help preserve the neuroscience research ecosystem with a particular focus on those areas where NINDS carries a unique and sole responsibility.
Our first area of responsibility is in training the next generation of neuroscientists. We must ensure that the most talented people considering this as a career, and those just starting with exciting, new ideas feel our support and see a sustainable path forward. Second is supporting fundamental, basic neuroscience research. No other entity in the research ecosystem specifically funds this area. One of the core reasons it is so difficult to develop treatments for neurological disorders is that we simply do not know enough about how the brain and nervous system function. You cannot effectively intervene when things go wrong if you do not understand how they are supposed to work. That investment represents approximately a quarter of our total research portfolio and it must be protected. Third, is translational research. Specifically the work of de-risking discoveries so that academic researchers who may not know how to move a finding forward can bring it to a state that makes it appealing to a biotech or pharmaceutical partner. And fourth is maintaining clinical research in areas that lack strong commercial appeal such as ultra rare disorders, or investigations that do not involve proprietary intellectual property. This is where we have a unique role to play precisely because the private sector cannot.
Neuroscience has historically been characterized by development hurdles and high failure rates. Do you believe the field is now at an inflection point?
What is exciting is that in recent years the scientific environment has been transformed by a decade of work through the NIH BRAIN Initiative. The Initiative has produced new tools and technologies that are allowing researchers to unlock an understanding of the human brain in ways that were simply unimaginable before. Unlike the heart or the liver, where we have long understood the cell types and how they compose a functioning organ, the brain has been a genuine mystery. It is only in the past few years that we have been able to say we mostly understand the different cell types that make up the brain, and we are only just beginning to understand how those cells are arranged and how they connect.
The complexity is extraordinary with 100 billion neurons and trillions of connections. However, the BRAIN Initiative has given us tools not just to begin mapping that complexity, but to target specific cell types and understand how particular neurons are connected in a circuit, and how that circuit controls a specific behavior. As that level of specificity becomes achievable, the possibilities for intervention, through molecules, devices, or genetic therapies open up in ways they never have before.
Brain-computer interfaces are one vivid example. The ability to restore communication to individuals with ALS or other neurodegenerative conditions is already extraordinary and is advancing rapidly. I am genuinely hopeful that the tools now emerging from the BRAIN Initiative will usher in a broader re-engagement with industry because the scientific foundation for productive partnership has never been stronger.
The other area I regard as potentially transformative is genetic therapies. One of the longstanding challenges with neurological disorders is that by the time a condition is fully symptomatic, so much neuronal damage has already occurred that halting progression, even if achievable, may not restore function. The dream has always been to intervene at the earliest possible point, before that deterioration begins. For genetic disorders, that means restoring appropriate genetic function before damage accumulates.
For a long time this felt more like science fiction than near-term science. But advances in recent years, in muscular dystrophy, in spinal muscular atrophy, and across a range of other conditions have shifted that perception dramatically. We are now beginning to test genetic therapies that can cross the blood-brain barrier and potentially have a direct impact on the human brain. The backbone of a reproducible, scalable approach is taking shape. I am genuinely excited about where this will lead.
Are there specific NINDS programs designed to advance genetic and genomic therapies for neurological conditions?
One important example is the Ultra Rare Gene-based Therapy Network (URGENT). This program is specifically designed to develop state-of-the-art gene-based therapies for ultra-rare neurological disorders. It encompasses both traditional gene therapy approaches, introducing a functional copy of a gene, and antisense oligonucleotide approaches, which use short strands of RNA or DNA to correct genetic mutations. Within our translational division, we support the development and planning for initial testing of these therapies with a structured handoff to our clinical research division to move them into clinical trials if development hits its milestones. We are beginning to see real progress here, and the enthusiasm within the program is high.
A second example is the somatic cell genome editing program, which PJ Brooks, director of NCATS’ Division of Rare Diseases Research Innovation, helps to lead with Tim Lavoie of our institute as co-lead. I co-chair that effort alongside Joni Rutter from the National Center for Advancing Translational Sciences. It is an extraordinarily important initiative, and one that represents precisely the kind of cross-institute, cross-discipline collaboration that is going to define the most impactful science going forward.
Genetic therapy and earlier intervention are clearly connected. How do you see the identification of novel biomarkers and improved diagnostic capabilities contributing to that goal?
Biomarker investment has been a long-standing priority at NINDS, and much of the most productive work has been done collaboratively. We have partnered with the National Institute on Aging to develop biomarkers not just for Alzheimer’s disease but for the related dementias. We have a large natural history program focused on biomarker development for amyotrophic lateral sclerosis (ALS), and a long-standing program in Parkinson’s disease biomarker research.
The value of biomarkers is twofold. They allow us to understand disease progression in detail, and they allow us to monitor the impact of potential treatments much earlier in the disease course by measuring whether an intervention is having a biological effect before clinical symptoms change. That is transformative for drug development. But I want to be precise about the process. There is first the discovery of a biomarker, and then the separate, expensive, and critically important process of clinical validation. Once a biomarker is clinically validated, it becomes enormously powerful. It can be deployed by industry partners in development programs, and it becomes part of the dialogue with the FDA, which is such an important partner in all of these efforts. Biomarkers are, in a sense, a tool. It is the development and utilization of new tools that is really changing what we can achieve in this field.
Artificial intelligence and computational approaches are reshaping research across all areas . Where do you see the greatest potential for AI in advancing neuroscience specifically, and are there NINDS programs focused on this?
AI has particular potential in neuroscience for several interconnected reasons. There is an intrinsic relationship between advances in AI and our understanding of how the human brain works. Historically, progress in one has informed the other, and that bidirectional exchange will continue and deepen. The human brain is by far the most efficient computational system on the planet. It had extraordinary processing capacity and speed, running on roughly the energy equivalent of a 20-watt light bulb. If we could meaningfully capture what makes that possible, the implications would be incredible.
More immediately, AI is essential for managing the scale of data that modern neuroscience generates. Our imaging capabilities have advanced dramatically, and as we reconstruct neural structures across multiple individuals and at increasingly fine scales of resolution, we need AI to help us analyze that data efficiently, effectively, and in an unbiased way. The same applies to single-cell sequencing technologies, which have been central to our ability to characterize the different cell types in the human brain, understand where they are located, and how they connect. That technology produces an extraordinary volume of sequencing data, and leveraging computational tools to make sense of it is essential.
Those same computational approaches are also becoming increasingly important in understanding how environmental exposures influence neurological health. The vast majority of neurological disorders have no known origin. We suspect environmental triggers in many cases, but we do not know what they are, whether they are singular or cumulative, or how they interact with genetic predispositions. Parkinson’s disease is a good example. There are some genetic forms, but the majority of cases are of unknown origin and are suspected to involve an environmental component.
We recently established the Neuro Exposome and Toxicology Program (NTOX) specifically to address this. The neuro exposome encompasses not just traditional environmental exposures but also metabolomics, the microbiome, and the full spectrum of internal and external environments that shape a person’s neurological health. Part of the challenge is methodological. We need new ways to capture environmental exposures, and then increasingly sophisticated computational approaches to sift through that data and identify signals genuinely relevant to health outcomes. It is another area where the intersection of biology, technology, and computation is going to be essential.
Alongside all of this must come careful, research-based consideration of the ethical implications of AI in neuroscience. We have a dedicated neuroethics research program specifically focused on scanning the horizon for these considerations. As we develop devices that modulate brain activity or record data from a living human brain, we have to resolve how can we assess that data, store it, and secure it.
Looking five to ten years ahead, where are you most hopeful about the trajectory of neurological research and its impact on patients?
I expect to see a dramatic improvement in our ability to map the specific circuits that regulate specific behaviors. That understanding will open up new possibilities for devices in particular. Deep brain stimulation already has the capacity to help regulate brain function in conditions like Parkinson’s disease, where certain circuits begin to misfire. But we are now developing adaptive versions of deep brain stimulation. These devices do not simply fire continuously but wait for a signal indicating a misfiring event is imminent and then intervene to calm the electrical storm before it fully develops. As our understanding of brain circuits becomes more precise and our ability to target interventions with greater specificity improves, the potential for devices to meaningfully change the experience of living with a neurological condition is going to expand considerably.
NINDS is responsible for hundreds of neurological conditions, both common and rare. I am optimistic that we will make significant progress across that spectrum. This includes many of the common conditions like stroke and Parkinson’s but also in ultra-rare disorders where advances in genetic intervention and our growing mechanistic understanding are combining to open doors that were previously closed. The goal for the next generation of neurologists is not just to support patients or ameliorate some of their symptoms, but to give them tools that genuinely and dramatically improve day-to-day life.
Stroke treatment over the past decade gives me real grounds for optimism. The ability to rapidly identify patients who will benefit from clot removal, and to intervene quickly enough that people who would otherwise have had catastrophic, life-altering strokes are able to walk out of the emergency room a few days later, that is a transformation in outcomes that has already happened. My hope is that over the next five to ten years we will generate more treatments with that kind of impact across the full range of conditions we are responsible for.
Do you have a final message to the broader life sciences and healthcare community about the importance of collaboration and partnership in advancing neurological research?
I never want to underestimate the power of the individual investigator pursuing a line of inquiry driven by scientific curiosity. That mode of research has been the engine of innovation for decades, and I fully support it. But increasingly, as the problems we are tackling grow more complex and the tools available to address them grow more sophisticated, the most significant discoveries are going to happen at the intersection of disciplines. Having teams across neuroscience, computational science, chemistry, chemical engineering, cell biology, and molecular science work together to unravel these mysteries is where the transformative advances will come from. Bringing diverse perspectives that can illuminate the same problem from multiple angles. Similarly, the opportunities for productive partnership between NINDS and the pharma and biotech community have never been greater, and I want those communities to know that we would welcome that partnership and that we are ready for it.
Another point I want to emphasize is that we engage people with lived experience of neurological disease at every stage of the journey. This matters deeply to how we work at NINDS. Patient input helps inform our research priorities and identify the right clinical endpoints. People with lived experience sit on our advisory committees and participate in our annual non-profit forum. They are experts in the lived experience of their disease. We recognize that, we respect it, and we look to incorporate that expertise into everything we do.
I will end by saying that NINDS is deeply committed to unraveling the mystery of the human brain. There is nothing more thrilling, more important, or more fundamentally human to study. The brain is our capacity to think, to remember, to feel, and to connect, and it is that capacity which defines us as humans.

